

Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus

NCT05898308

Status	RECRUITING
Phase	Phase 4
Sponsor	University Hospital, Rouen
Enrollment	133 participants

Key Eligibility Criteria

Inclusion (13)

- Age e 18 and d 80 years
 - Signed Informed Consent Form (or from the family in case of impossibility of patient's consent).
 - Confirmed newly diagnosed PV or PF, based on the presence of the following: histological features of acantholysis on skin or mucosal biopsy, and deposition of IgG, complement component 3, or both on the keratinocyte membrane detected by direct immunofluorescence on affected skin or mucosa
 - Presence of moderate-to-severely active disease, defined by an overall PDAI score > 1554
 - Patient able to receive the standard-of-care consisting of corticosteroids (prednisone 1 mg/kg/day PO) and rituximab
- ... and 8 more (see full listing online)

Exclusion (28)

- Non-consenting patient or patient who cannot be followed regularly.
 - Diagnosis of paraneoplastic pemphigus or evidence of other non-PV or PF autoimmune blistering disease
 - Contraindication to rituximab marketed as 500 mg concentrate for solution for infusion
 - Contraindication to prednisone marketed as 20 mg, scored tablet pharmaceutical form
 - Contraindication to methylprednisolone marketed as 120 mg powder for injectable solution pharmaceutical form
- ... and 23 more (see full listing online)

Locations (34 total)

Chu Amiens, Amiens, France
Chu Angers, Angers, France
Ch Argenteuil, Argenteuil, France
... and 31 more locations